This case study shows how MedPharm demonstrated the clinical efficacy and tolerability of MedSpray® in a non-inferiority study against a marketed antifungal treatment. Building on strong preclinical performance, the optimized MedSpray® formulation delivered equivalent antifungal activity while improving tolerability and maintaining comparable recurrence rates. These results confirm that enhanced topical drug delivery can translate into meaningful clinical outcomes and support both regulatory and commercial success.
